# Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.

Study · id `cardio:ct-nct01768702` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01768702](<https://clinicaltrials.gov/study/NCT01768702>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01768702

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

## Technical summary

Registry record NCT01768702. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2017-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 315 participants (enrolled count; ClinicalTrials.gov record NCT01768702, source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)
- Start date: 2012-11 (registry gives no type) (ClinicalTrials.gov record NCT01768702, source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)
- Primary completion: 2017-08 (actual) (ClinicalTrials.gov record NCT01768702, source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)
- Completion: 2017-08 (actual) (ClinicalTrials.gov record NCT01768702, source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)
- Countries: Belgium; Bulgaria; Hungary; Israel; Italy; Poland; Serbia; Spain; Switzerland (ClinicalTrials.gov record NCT01768702, source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01768702-2018-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
- Acronym: CHART-1
- Condition: Heart Failure
- Intervention (Biological): Injection of C3BS-CQR-1
- Intervention (Biological): Sham, no injection
- Lead sponsor: Celyad Oncology SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 2db75604de63a5d08b640e9fa08a2177242d279bd5a7b8f2d31b3e2cd4a23017
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
